Wellington Management Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.58M | Sell |
7,906
-520
| -6% | -$103K | ﹤0.01% | 1593 |
|
|
2025
Q4 | $1.59M | Buy |
8,426
+110
| +1% | +$21.1K | ﹤0.01% | 1643 |
|
|
2025
Q3 | $1.47M | Buy |
8,316
+946
| +13% | +$141K | ﹤0.01% | 1710 |
|
|
2025
Q2 | $838K | Sell |
7,370
-192
| -3% | -$20.5K | ﹤0.01% | 1745 |
|
|
2025
Q1 | $795K | Sell |
7,562
-41
| -0.5% | -$4.64K | ﹤0.01% | 1754 |
|
|
2024
Q4 | $815K | Sell |
7,603
-1,085
| -12% | -$123K | ﹤0.01% | 1753 |
|
|
2024
Q3 | $870K | Sell |
8,688
-5,714
| -40% | -$575K | ﹤0.01% | 1738 |
|
|
2024
Q2 | $1.21M | Buy |
14,402
+1,854
| +15% | +$148K | ﹤0.01% | 1630 |
|
|
2024
Q1 | $917K | Sell |
12,548
-2,139
| -15% | -$158K | ﹤0.01% | 1705 |
|
|
2023
Q4 | $1.05M | Buy |
+14,687
| New | +$867K | ﹤0.01% | 1617 |
|
|
2020
Q1 | – | Sell |
-268,387
| Closed | -$17.5M | – | 1992 |
|
|
2019
Q4 | $17.5M | Sell |
268,387
-7,044
| -3% | -$471K | ﹤0.01% | 1023 |
|
|
2019
Q3 | $17.1M | Sell |
275,431
-10,414
| -4% | -$654K | ﹤0.01% | 1010 |
|
|
2019
Q2 | $20.4M | Buy |
285,845
+10,462
| +4% | +$771K | ﹤0.01% | 1004 |
|
|
2019
Q1 | $21.6M | Buy |
+275,383
| New | +$20.9M | ﹤0.01% | 996 |
|
|
2018
Q3 | – | Sell |
-6,803
| Closed | -$879K | – | 2271 |
|
|
2018
Q2 | $879K | Sell |
6,803
-1,148
| -14% | -$128K | ﹤0.01% | 1919 |
|
|
2018
Q1 | $819K | Buy |
7,951
+66
| +0.8% | +$6.53K | ﹤0.01% | 1932 |
|
|
2017
Q4 | $674K | Hold |
7,885
| – | – | ﹤0.01% | 1992 |
|
|
2017
Q3 | $670K | Hold |
7,885
| – | – | ﹤0.01% | 1984 |
|
|
2017
Q2 | $597K | Buy |
+7,885
| New | +$552K | ﹤0.01% | 2000 |
|
|
2016
Q1 | – | Sell |
-31,332
| Closed | -$2.12M | – | 2177 |
|
|
2015
Q4 | $2.12M | Sell |
31,332
-8,773
| -22% | -$542K | ﹤0.01% | 1609 |
|
|
2015
Q3 | $2.14M | Buy |
40,105
+19,665
| +96% | +$1.19M | ﹤0.01% | 1616 |
|
|
2015
Q2 | $1.29M | Sell |
20,440
-28,484
| -58% | -$1.55M | ﹤0.01% | 1784 |
|
|
2015
Q1 | $2.35M | Sell |
48,924
-9,778
| -17% | -$375K | ﹤0.01% | 1646 |
|
|
2014
Q4 | $1.95M | Sell |
58,702
-4,328
| -7% | -$141K | ﹤0.01% | 1693 |
|
|
2014
Q3 | $1.85M | Buy |
63,030
+21,810
| +53% | +$724K | ﹤0.01% | 1695 |
|
|
2014
Q2 | $1.6M | Buy |
41,220
+953
| +2% | +$38.7K | ﹤0.01% | 1718 |
|
|
2014
Q1 | $1.69M | Sell |
40,267
-309,564
| -88% | -$12.9M | ﹤0.01% | 1726 |
|
|
2013
Q4 | $11.5M | Sell |
349,831
-476,091
| -58% | -$15.5M | ﹤0.01% | 1194 |
|
|
2013
Q3 | $22.3M | Sell |
825,922
-140,102
| -15% | -$3.94M | 0.01% | 954 |
|
|
2013
Q2 | $22.6M | Buy |
+966,024
| New | +$17.4M | 0.01% | 936 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Wellington Management Group's LGND Position: Q1 2026 in Review
Wellington Management Group reduced its Ligand Pharmaceuticals (LGND) stake by 6.2% in Q1 2026, selling an estimated $103K and leaving 7,906 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1593.
Wellington Management Group first reported a position in LGND in Q2 2013 and has held it in 30 quarters since. The position peaked at $22.6M in Q2 2013. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Wellington Management Group held 7,906 shares of Ligand Pharmaceuticals worth $1.58M as of Q1 2026.
- Wellington Management Group sold 520 Ligand Pharmaceuticals shares in Q1 2026, an estimated $103K.
- Ligand Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1593 holding.
- Wellington Management Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
- Wellington Management Group's Ligand Pharmaceuticals position peaked at $22.6M in Q2 2013.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.